Literature DB >> 8015078

Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer?

J B Thrasher1, H A Frazier, J E Robertson, D F Paulson.   

Abstract

Controversy exists regarding the clinical significance of a pathological stage T0 (pT0) specimen found at cystectomy or after repeat transurethral resection for transitional cell carcinoma of the bladder. Many investigators cite this subpopulation of patients as a reason to consider more conservative management, based on the premise that the patient may have benefited from the original transurethral resection. However, we questioned whether outcome would be improved in stage pT0 cancer patients or whether outcome in stage pT0 cases would parallel that noted when the original stage was equivalent to the final pathological stage. To test this hypothesis, we examined the survival advantage occasioned by a stage pT0 finding in 66 of 433 patients who underwent radical cystectomy for transitional cell carcinoma of the bladder. Of the 433 patients studied 54 had clinical stage Tis or Ta, 166 clinical stage T1 and 213 clinical stage T2 disease. Within each of the 3 clinical groups (clinical stage Tis/Ta, clinical stage T1 and clinical stage T2) Kaplan-Meier survival projections were generated comparing patients with stage pT0 disease to those whose pathological stage was identical to the original clinical stage. Among the 54 clinical stage Tis/Ta cancer patients 11 with stage pT0 and 24 with stage pTis/pTa had survival projections of 90% of 5 years. Of 166 patients with clinical stage T1 disease 32 with stage pT0 and 78 with stage pT1 tumor had survival projections of 75% at 5 years. Among 213 patients with clinical stage T2 cancer 23 with stage pT0 and 71 with stage pT2 disease had survival projections of 68% at 5 years. The data suggest that a stage pT0 cystectomy specimen does not confer a survival advantage over that noted from the initiating population in which the final pathological stage and initial clinical stage are equivalent. A patient with a stage pT0 specimen functions, by survival analysis, in a manner similar to one with the stated clinical stage.

Entities:  

Mesh:

Year:  1994        PMID: 8015078     DOI: 10.1016/s0022-5347(17)32746-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

1.  Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease.

Authors:  Matthew K Tollefson; Stephen A Boorjian; Sara A Farmer; Igor Frank
Journal:  World J Urol       Date:  2012-03-25       Impact factor: 4.226

2.  Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience.

Authors:  Gurdarshan S Sandhu; Armen Aprikian; Joseph Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; David Bell; Wassim Kassouf; Darrel Drachenberg
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

3.  Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.

Authors:  Timur Mitin; Daniel Hunt; William U Shipley; Donald S Kaufman; Robert Uzzo; Chin-Lee Wu; Mark K Buyyounouski; Howard Sandler; Anthony L Zietman
Journal:  Lancet Oncol       Date:  2013-07-01       Impact factor: 41.316

4.  P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.

Authors:  Wassim Kassouf; Philippe E Spiess; Gordon A Brown; Mark F Munsell; H Barton Grossman; Arlene Siefker-Radtke; Colin P N Dinney; Ashish M Kamat
Journal:  Eur Urol       Date:  2007-04-10       Impact factor: 20.096

5.  Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Authors:  Willemien Beukers; Titia Meijer; Cornelis J Vissers; Joost L Boormans; Ellen C Zwarthoff; Geert J L H van Leenders
Journal:  Virchows Arch       Date:  2012-07-10       Impact factor: 4.064

6.  Downstaging of TURBT-Based Muscle-Invasive Bladder Cancer by Radical Cystectomy Predicts Better Survival.

Authors:  P R van Dijk; M Ploeg; K K H Aben; P C Weijerman; H F M Karthaus; J Th H van Berkel; A C Viddeleer; A Geboers; E van Boven; J A Witjes; L A L M Kiemeney
Journal:  ISRN Urol       Date:  2011-04-27

7.  Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.

Authors:  Severin Rodler; Alexander Buchner; Lennert Eismann; Gerald Bastian Schulz; Julian Marcon; Stephan Ledderose; Boris Schlenker; Christian G Stief; Alexander Karl; Jan-Friedrich Jokisch
Journal:  Res Rep Urol       Date:  2022-08-01

Review 8.  The role of a second transurethral resection for high-grade bladder cancer.

Authors:  P Langenstroer; W See
Journal:  Curr Urol Rep       Date:  2000-10       Impact factor: 2.862

Review 9.  Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.

Authors:  Omar M S El-Taji; Sameer Alam; Syed A Hussain
Journal:  Curr Treat Options Oncol       Date:  2016-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.